In analyzing two-year data from SightGlass Vision’s CYPRESS clinical trial, experts have learned that the spectacle lenses were effective at controlling myopia in 6- and 7-year-olds. SightGlass Vision’s Diffusion Optics Technology (DOT) reduced both axial length (mean absolute reduction = 0.27 mm) and cycloplegic SER progression (mean absolute reduction = 0.77D) in 6- and 7-year-old children versus the control. The focus on age is of particular interest to eyecare professionals and researchers, as myopia progresses fastest in the youngest children. Since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health. Read More